DUBLIN, March 1, 2018 /PRNewswire/ --

The "Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017" report has been added to ResearchAndMarkets.com's offering.

Cervical intraepithelial neoplasia (CIN), also known as cervical dysplasia is characterized by abnormal appearance of cells on the surface of the cervix. Cervical dysplasia usually occurs in women aging twenty five to thirty five. Most cases of cervical dysplasia are caused by human papilloma virus (HPV). There are a total of 163 products in development for this indication, by 118 companies and 25 academic institutions. Key companies operating in this pipeline space include Advaxis, F. Hoffmann-La Roche, GlaxoSmithKline, Kite Pharma, MedImmune and Pfizer.

The most prominent targets in the cervical cancer pipeline are HPV proteins there are a number of products in the pipeline targeting HPV protein E7 and HPV protein E6. Other common targets in the pipeline include vascular endothelial growth factor A and programmed cell death protein 1.

Vaginal cancer is a rare cancer that causes symptoms such as watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. There are a total of 6 products in development for this indication, by 6 companies. The companies operating in this pipeline space are ISA Pharmaceuticals, MedImmune, Ology Bioservices, Ono Pharmaceutical, Oryx GmbH & Co KG and Taiwan Liposome Company.

Finally, Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. There are a total of 5 products in development for this indication, by 5 companies. The five companies operating in this pipeline are Cutanea Life Sciences, ISA Pharmaceuticals, MedImmune, Ono Pharmaceutical and Oryx GmbH & Co KG

The report "Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017" provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervical Cancer, Vaginal Cancer and Vulvar Cancer, and features dormant and discontinued projects.

Scope

• Which companies are the most active within the pipeline for genetic ophthalmological disorder therapeutics?
• Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
• What are the most important R&D milestones and data publications to have happened in the field of genetic ophthalmological disorders?

Reasons to buy

• Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
• Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
• Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
• Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

Key Topics Covered:

• Therapeutics Development
  
• Therapeutics Assessment
  
• Companies Involved in Therapeutics Development
  
• Dormant Projects
  
• Discontinued Products
  
• Product Development Milestones
  

Companies Mentioned

• Abion Inc
• Abivax SA
• Admedus Ltd
• Arbor Vita Corp
• ArQule Inc
• Asana BioSciences LLC
• AstraZeneca Plc
• AVEO Pharmaceuticals Inc
• Bayer AG
• BeiGene Ltd
• Bioleaders Corp
• Biomics Biotechnologies Co Ltd
• Critical Outcome Technologies Inc
• Cutanea Life Sciences Inc
• Cytori Therapeutics Inc
• CZ BioMed Corp
• DelMar Pharmaceuticals Inc
• Dr. Reddy's Laboratories Ltd
• Eisai Co Ltd
• Etubics Corp
• Eureka Therapeutics Inc
• EyeGene Inc
• Iovance Biotherapeutics Inc
• ISA Pharmaceuticals BV
• Johnson & Johnson
• Juno Therapeutics Inc
• Kaketsuken
• Karyopharm Therapeutics Inc
• Kite Pharma Inc
• LondonPharma Ltd
• Mabion SA
• MedImmune LLC
• Merck & Co Inc
• Merck KGaA
• Mycenax Biotech Inc
• Ono Pharmaceutical Co Ltd
• Oryx GmbH & Co KG
• PDS Biotechnology Corp
• Pfizer Inc
• Pharma Mar SA
• Psicofarma SA de CV
• Puma Biotechnology Inc
• Regeneron Pharmaceuticals Inc
• Rexahn Pharmaceuticals Inc
• Richter Gedeon Nyrt
• Samyang Holdings Corp
• Sanofi
• Sirnaomics Inc
• Sun Pharma Advanced Research Company Ltd
• Taiwan Liposome Company Ltd
• Tessa Therapeutics Pte Ltd
• UbiVac LLC
• Vectorite Biomedica Inc
• VLPbio
• Wellstat Biologics Corp
• Zeria Pharmaceutical Co Ltd

For more information about this report visit https://www.researchandmarkets.com/research/drw923/lower_female?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/lower-female-reproductive-system-cancers-drug-development-pipeline-review-2017-300606842.html

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com